Form 4: CEO Rothblatt Exercises Options, Sells UTHR Shares

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed transactions on March 16, 2026.
• These transactions involved the exercise of 9,500 stock options at an exercise price of $146.03 per share.
• Concurrently, 9,500 shares of common stock were sold in multiple trades at weighted average prices ranging from $529.1624 to $537.37.
• The transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, direct beneficial ownership of common stock decreased to 40,513 shares.
• Indirect beneficial ownership includes 166 shares by spouse and 639,193 shares across various family trusts.
• The reporting person still beneficially owns 135,500 derivative stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales under a pre-arranged 10b5-1 plan, which typically do not convey new information about the company's fundamental performance or outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating planned and transparent insider activity.
• The sale prices for the common stock (ranging from $529.1624 to $537.37) are significantly higher than the option exercise price ($146.03), indicating a profitable transaction for the insider.

Negatives

• The CEO's direct beneficial ownership of common stock decreased by 9,500 shares, which could be interpreted as a reduction in direct exposure to the company's equity.

Future Outlook

The pre-arranged 10b5-1 trading plan, adopted on November 7, 2025, is set to continue until the earlier of the exercise of 1,734,410 stock options (which expire on March 17, 2027) or December 31, 2026.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are a routine aspect of executive compensation and personal financial management. These pre-scheduled sales typically do not reflect a change in management's outlook on the company's future performance, unlike unscheduled open market sales.

Comparison to Industry Standards

• NA. This filing details individual insider transactions rather than company performance metrics, making direct comparisons to industry-wide operational or financial benchmarks inapplicable. The execution of a 10b5-1 plan is a standard practice for corporate insiders to manage their equity holdings in a compliant manner.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be perceived as a slight reduction in direct insider alignment, though the pre-arranged nature mitigates negative interpretations. The remaining significant indirect holdings through trusts maintain substantial alignment.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continuation of the 10b5-1 trading plan until the earlier of the exercise of 1,734,410 stock options or December 31, 2026.

Key Dates

Recommendation

The filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan. These types of sales are generally expected and do not typically provide new material information that would warrant a change in investment recommendation. The CEO maintains significant indirect ownership, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present new catalysts for a 'buy' or 'sell' decision.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Beneficial Ownership